Immunotech Laboratories BG announced the successful ITV-1 clinical trials Final Report completion

The conclusions about the results from ITV-1 clinical trials: 1. The application of the product ITV-1 shows good efficacy in patients with HIV-1 infection in its various stages – in 21 of them (68%) from the main group we note an increase in CD4 + T- lymphocytes; in 16 of…

Immunotech Laboratories BG announced successful completion of ITV-1 clinical trials on HIV/AIDS patients

Research Center: Department for treatment of acquired immune deficiency at the Specialized Hospital for Active Treatment of Infectious And Parasite Diseases – “Prof. Ivan Kirov”, Sofia, Bulgaria. Testing on human-volunteers, with HIV/AIDS, in whom ITV-1 has shown to be harmless, without any side effects, good tolerance, and a good treatment…

Immunotech Laboratories BG announced the successful approvement of ITV-1 clinical trials on HIV/AIDS patients in Bulgaria

Plan for the clinical trial The patients in the experimental group will conduct a total of 32 visits to the center for the clinical trial, and each therapeutic course will include 16 patient visits, with a break of 12 days between the two courses. The patients in the control group…

The Petition of Immunotech Laboratories, Inc. for Termination of Trading Suspension

The Issuer is a Nevada corporation with its principal business location in Monrovia, California. The Issuer’s common equity securities are traded on the OTC Link (“Pink Sheets”) under the ticker “IMMB”. The Issuer is not subject to reporting obligations found under Section 13 of the Exchange Act[3]. However, the Issuer…

The Securities and Exchange Commission suspended trade in four over-the-counter Ebola-related stocks

The Securities and Exchange Commission suspended trade in four over-the-counter Ebola-related stocks: Bravo Enterprises (OGNG), Immunotech Laboratories (IMMB), Myriad Interactive Media (MYRY) and Wholehealth Products (GWPC). The SEC cited a lack of publicly available information about the companies’ operations. The SEC can suspend trading in a stock for 10 days and generally…

Immunotech Laboratories, Inc. (IMMB) today released company updates for shareholders and Investors

Immunotech Laboratories Inc. , A Nevada Corporation,(IMMB), is pleased to announce that the financials for the company have been completed and are currently being audited. Blaine Nabors VP of Business Development today said Immunotech’s financials are now complete and now is in the hands of our Auditor, Travis Green, DKM…

Immunotech Laboraties, Inc. Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status

Immunotech Laboratories, Inc. (IMMB) today announced the company signed an agreement with The Lebrecht Group, a professional law corporation, to provide legal services for Immunotech and to upgrade the company to OTC:BB fully reporting current status. Immunotech Founder, President and Chief Science Officer Harry Zhabilov today commented, “This step will help assure…

Immunotech Laboratories, Inc. signed a contract with partner in Bulgaria to register a company called Immunotech Laboratories B.G. LLC

Immunotech Laboratories, Inc. (IMMB) signed a contract with strategic partners in Bulgaria to register a company called Immunotech Laboratories B.G. LLC. Immunotech Laboratories, Inc. will own 49% of the Bulgarian subsidiary. The goal of Immunotech Laboratories BG is to conduct pre-clinical testing, clinical trials phase I, phase II, and phase…

Immunotech Laboratories Agreement with Viral Genetics Inc.

In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims…